secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0000950170-24-098049
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma enters new employment agreement with CEO Prashant Kohli
---------------------------------------------------------------------

- Annual base salary of $500,000 and eligible for discretionary bonus up to 50% of base.
- Severance of 12 months' base salary if terminated without cause (including after change of control).
- Subject to board approval, may receive stock options under the company's equity incentive plan.
- 12-month non-compete and non-solicitation clauses; standard benefits and vacation included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024098049/0000950170-24-098049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024098049/acst-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-098049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer